Home>Topics>Stocks>Abiomed

Abiomed ABMD

  1. All
  2. Commentary
  3. Headlines
    1. A Young Power Couple's Kickstart Portfolio

      Headlines

      Fri, 6 Jun 2014

      Holding Market Value ($) Weight (%) Star Rating Matt's Roth IRA: Cash 5,263 1.96 N/A Matt's Roth IRA: Abiomed ABMD 184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals

    2. Dropping Coverage of Abiomed

      Commentary

      Wed, 18 Dec 2013

      We are no longer providing equity research on Abiomed . We provide broad coverage of more than 1,800 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    3. Abiomed Back on Track in 2Q, Following Weak Beginning of Fiscal Year

      Commentary

      Wed, 13 Nov 2013

      Abiomed reported strong fiscal second-quarter ..... largely consistent with our expectations. Abiomed remains on track to reach our full-year ..... continues to grow, which supports our view of Abiomed 's positive moat trend. We think there

    4. Abiomed Posts Weak First Quarter, but Our Fair Value Estimate Is Unchanged

      Commentary

      Thu, 1 Aug 2013

      Abiomed reported fiscal first-quarter performance ..... variance from quarter to quarter, we think Abiomed can still reach our full-year projections ..... nascent stage of the acute VAD market that Abiomed is still pioneering, we do not think the

    5. Thoratec Delivers Strong 2Q Following Anemic 1Q

      Commentary

      Thu, 1 Aug 2013

      unlikely to reach commercialization before 2017. Even though it will be several years before the PHP product is marketable, it nonetheless provides Thoratec with important entree to the acute VAD niche that is currently dominated by Abiomed .

    6. Abiomed Sales Rise Past Estimates

      Commentary

      Wed, 17 Apr 2013

      On Wednesday, Abiomed ABMD released preliminary fourth-quarter ..... our positive moat trend rating for Abiomed . Although we do not believe the firm ..... yet, momentum continues to build for Abiomed with the U.S. release of Impella

    7. Abiomed Meets Expectations in 3Q

      Commentary

      Wed, 6 Feb 2013

      turbulence on the regulatory front, Abiomed ABMD remained on track operationally ..... set as the CP gains traction in Abiomed 's key geographic market during ..... the quarter (19% of sales), Abiomed maintains a healthy financial position

    8. FDA Panel Recommends Device Classification That Changes Regulatory Pathway for Abiomed's Impella

      Commentary

      Fri, 7 Dec 2012

      trim our fair value estimate for Abiomed ABMD to $17 per share from $18. Because ..... increase the cost of doing business for Abiomed and any other firm that wants to ..... device, meaning some didn't think Abiomed should be forced to collect additional

    9. Abiomed Revs Up Profitability

      Commentary

      Thu, 2 Aug 2012

      Abiomed ABMD turned in first-quarter results that ..... value estimate significantly. Of note, Abiomed appears to be trading on the speculation ..... from this level. During the quarter, Abiomed 's growth remained on a high trajectory

    10. Lazard downgrades Abiomed on Impella reimbursement concerns

      Headlines

      Tue, 22 May 2012

      (Reuters) - Shares in medical device maker Abiomed Inc could remain under pressure due to concerns about any possible reimbursement issue with its Impella heart pump, said brokerage Lazard Capital...

    « Prev12345Next »
    Content Partners